For General Information, page-790

happy that he discussed that we are going into the EU trial, still the focus of the company:

"we know that shareholders are watching very closely as we advance into a pivotal study in Europe so that still is the main game for the company but we think being able to run these research studies along side that doesn't take the company's focus away from the main program. .. adds value in an are that we know very well. ... some very large indications there that we know that the drug could have great potential in, and we will bring them on, we will bring them on over time as we steadily advance in Duchennes, ...we will add resources, human resources to move in to these other areas..."

Let's call that a reassurance progress update, and wait for this price sensitive trial update.